Loading market dashboard

Financials in USD. Standardized financial statements.
A compact view of how Beam Therapeutics Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $139.74M | $63.52M | $377.71M | $60.92M | $51.84M | $24,000 | $18,000 | $0 | $0 |
| Revenue Growth? | +120.0% | -83.2% | +520.0% | +17.5% | +215916.7% | +33.3% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $22.29M | $367.56M | $0 | $311.59M | $232.13M | $103.18M | $54.62M | $33.87M | $0 |
| Gross Profit? | $117.45M | -$304.04M | $377.71M | -$250.67M | -$180.29M | -$103.16M | -$54.60M | -$33.87M | $0 |
| Gross Margin? | +84.0% | -478.7% | +100.0% | -411.5% | -347.8% | -429812.5% | -303338.9% | 0.0% | 0.0% |
| Operating Expenses? | $501.14M | $111.53M | $554.19M | $87.81M | $212.18M | $29.60M | $20.55M | $11.87M | $8.60M |
| Operating Income? | -$383.69M | -$415.57M | -$176.49M | -$338.48M | -$392.46M | -$132.76M | -$75.15M | -$45.74M | -$8.60M |
| EBITDA? | -$29.92M | -$393.64M | -$146.95M | -$324.33M | -$230.06M | -$128.03M | -$71.65M | -$45.09M | -$8.58M |
| Income Before Tax | -$79.99M | -$376.70M | -$131.16M | -$285.68M | -$370.64M | -$194.59M | -$78.33M | -$116.74M | -$8.73M |
| Income Tax Expense | $0 | $39,000 | $1.37M | $3.41M | $0 | $0 | $0 | $0 | $500,000 |
| Net Income? | -$79.99M | -$376.74M | -$132.53M | -$289.09M | -$370.64M | -$194.59M | -$78.33M | -$115.26M | -$8.73M |
| EPS? | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 | $-5.49 | $-1.53 | $-3.28 | $-0.62 |
| Diluted EPS? | $-0.81 | $-4.58 | $-1.72 | $-4.13 | $-5.77 | $-5.49 | $-1.53 | $-3.28 | $-0.62 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality